

## CLNE0020: Motoneurons, Neuromuscular Junctions and Associated Disease

[View Online](#)

1.

Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. *Expert Opinion on Investigational Drugs*. 2012 Mar;21(3):297–320. doi:10.1517/13543784.2012.657303

2.

Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? *The Lancet Neurology*. 2014 Nov;13(11):1127–38. doi:10.1016/S1474-4422(14)70129-2

3.

Maragakis NJ. What can we learn from the edaravone development program for ALS? *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2017 Oct 31;18(sup1):98–103. doi:10.1080/21678421.2017.1361446

4.

Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. *British Journal of Pharmacology*. 2011 Mar;162(6):1239–49. doi:10.1111/j.1476-5381.2010.01127.x

5.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *The Lancet Neurology*. 2018 Mar;17(3):251–67. doi:10.1016/S1474-4422(18)30024-3

6.

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *The Lancet Neurology*. 2018 Apr;17(4):347–61. doi:10.1016/S1474-4422(18)30025-5

7.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *The Lancet Neurology*. 2018 May;17(5):445–55. doi:10.1016/S1474-4422(18)30026-7

8.

Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscular Disorders*. 2018 Feb;28(2):103–15. doi:10.1016/j.nmd.2017.11.005

9.

Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscular Disorders*. 2018 Mar;28(3):197–207. doi:10.1016/j.nmd.2017.11.004

10.

Scoto M, Finkel RS, Mercuri E, Muntoni F. Therapeutic approaches for spinal muscular atrophy (SMA). *Gene Therapy*. 2017 Sep;24(9):514–9. doi:10.1038/gt.2017.45

11.

Ramsey D, Scoto M, Mayhew A, Main M, Mazzone ES, Montes J, et al. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. *PLOS ONE*. 2017 Feb 21;12(2). doi:10.1371/journal.pone.0172346

12.

Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. *Muscle & Nerve*. 2017 Jun;55(6):869–74. doi:10.1002/mus.25430

13.

Westerberg E, Molin CJ, Spörndly Nees S, Widenfalk J, Punga AR. The impact of physical exercise on neuromuscular function in Myasthenia gravis patients. *Medicine*. 2018 Aug;97(31). doi:10.1097/MD.00000000000011510

14.

Peragallo JH. Pediatric Myasthenia Gravis. *Seminars in Pediatric Neurology*. 2017 May;24(2):116–21. doi:10.1016/j.spen.2017.04.003

15.

Laurá M, Singh D, Ramdharry G, Morrow J, Skorupinska M, Pareyson D, et al. Prevalence and orthopedic management of foot and ankle deformities in Charcot-Marie-Tooth disease. *Muscle & Nerve*. 2018 Feb;57(2):255–9. doi:10.1002/mus.25724

16.

Reilly MM, Pareyson D, Burns J, Laurá M, Shy ME, Singh D, et al. 221st ENMC International Workshop: Neuromuscular Disorders. 2017 Dec;27(12):1138–42. doi:10.1016/j.nmd.2017.09.005

17.

Ramdharry GM, Pollard A, Anderson C, Laurá M, Murphy SM, Dudziec M, et al. A pilot study of proximal strength training in Charcot-Marie-Tooth disease. *Journal of the Peripheral Nervous System*. 2014 Dec;19(4):328–32. doi:10.1111/jns.12100

18.

Gibson S, Haringer V. Amyotrophic lateral sclerosis: clinical perspectives. *Orphan Drugs: Research and Reviews*. 2015 Apr. doi:10.2147/ODRR.S63585

19.

Berlowitz DJ, Howard ME, Fiore JF, Vander Hoorn S, O'Donoghue FJ, Westlake J, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016 Mar;87(3):280–6. doi:10.1136/jnnp-2014-310055

20.

Harwood CA, McDermott CJ, Shaw PJ. Clinical aspects of motor neurone disease. *Medicine*. 2012 Oct;40(10):540–5. doi:10.1016/j.mpmed.2012.07.003

21.

Drory VE, Goltsman E, Goldman Reznik J, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*. 2001 Oct;191(1–2):133–7. doi:10.1016/S0022-510X(01)00610-4

22.

Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. *Nature Reviews Neurology*. 2017 Feb;13(2):96–104. doi:10.1038/nrneurol.2016.182

23.

Carrì MT, D'Ambrosi N, Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. *Biochemical and Biophysical Research Communications*. 2017 Feb;483(4):1187–93. doi:10.1016/j.bbrc.2016.07.055

24.

Lin G, Mao D, Bellen HJ. Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. In: *Fly Models of Human Diseases* [Internet]. Elsevier; 2017. p. 111–71. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0070215316301454>

doi:10.1016/bs.ctdb.2016.07.004

25.

Monahan Z, Shewmaker F, Pandey UB. Stress granules at the intersection of autophagy and ALS. *Brain Research*. 2016 Oct;1649:189–200. doi:10.1016/j.brainres.2016.05.022

26.

Ruegsegger C, Saxena S. Proteostasis impairment in ALS. *Brain Research*. 2016 Oct;1648:571–9. doi:10.1016/j.brainres.2016.03.032

27.

Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. *Nature Neuroscience*. 2014 Jan;17(1):17–23. doi:10.1038/nn.3584

28.

Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nature Reviews Genetics*. 2000 Oct;1(1):20–9. doi:10.1038/35049541

29.

Harland R. Neural induction. *Current Opinion in Genetics & Development*. 2000 Aug;10(4):357–62. doi:10.1016/S0959-437X(00)00096-4

30.

Dasen JS, Jessell TM. Chapter Six Hox Networks and the Origins of Motor Neuron Diversity. In: *Hox Genes* [Internet]. Elsevier; 2009. p. 169–200. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S007021530988006X>  
doi:10.1016/S0070-2153(09)88006-X

31.

Bonanomi D, Pfaff SL. Motor Axon Pathfinding. *Cold Spring Harbor Perspectives in Biology*.

2010 Mar 1;2(3):a001735-a001735. doi:10.1101/cshperspect.a001735

32.

Darabid H, Perez-Gonzalez AP, Robitaille R. Neuromuscular synaptogenesis: coordinating partners with multiple functions. *Nature Reviews Neuroscience*. 2014 Nov;15(11):703–18. doi:10.1038/nrn3821

33.

Kanning KC, Kaplan A, Henderson CE. Motor Neuron Diversity in Development and Disease. *Annual Review of Neuroscience*. 2010 Jun;33(1):409–40. doi:10.1146/annurev.neuro.051508.135722

34.

Ladle DR, Pecho-Vrieseling E, Arber S. Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms. *Neuron*. 2007 Oct;56(2):270–83. doi:10.1016/j.neuron.2007.09.026

35.

Brownstone RM, Bui TV. Spinal interneurons providing input to the final common path during locomotion. In: *Breathe, Walk and Chew: The Neural Challenge: Part I* [Internet]. Elsevier; 2010. p. 81–95. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B978044453613600006X> doi:10.1016/B978-0-444-53613-6.00006-X

36.

Li L, Xiong WC, Mei L. Neuromuscular Junction Formation, Aging, and Disorders. *Annual Review of Physiology*. 2018 Feb 10;80(1):159–88. doi:10.1146/annurev-physiol-022516-034255

37.

Singhal N, Martin PT. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. *Developmental Neurobiology*. 2011 Nov;71(11):982–1005. doi:10.1002/dneu.20953

38.

Nishimune H, Valdez G, Jarad G, Moulson CL, Müller U, Miner JH, et al. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. *The Journal of Cell Biology*. 2008 Sep 22;182(6):1201–15. doi:10.1083/jcb.200805095

39.

Rudolf R, Khan MM, Labeit S, Deschenes MR. Degeneration of Neuromuscular Junction in Age and Dystrophy. *Frontiers in Aging Neuroscience*. 2014 May 22;6. doi:10.3389/fnagi.2014.00099

40.

Jones RA, Harrison C, Eaton SL, Llaverro Hurtado M, Graham LC, Alkhamash L, et al. Cellular and Molecular Anatomy of the Human Neuromuscular Junction. *Cell Reports*. 2017 Nov;21(9):2348–56. doi:10.1016/j.celrep.2017.11.008

41.

O'Connor E, Töpf A, Zahedi RP, Spendiff S, Cox D, Roos A, et al. Clinical and research strategies for limb-girdle congenital myasthenic syndromes. *Annals of the New York Academy of Sciences*. 2018 Jan;1412(1):102–12. doi:10.1111/nyas.13520

42.

Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. *The Lancet Neurology*. 2015 Apr;14(4):420–34. doi:10.1016/S1474-4422(14)70201-7

43.

Cruz PMR, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. *Current Opinion in Neurology*. 2014 Oct;27(5):566–75. doi:10.1097/WCO.0000000000000134

44.

Rodríguez Cruz PM, Palace J, Beeson D. Inherited disorders of the neuromuscular junction: an update. *Journal of Neurology*. 2014 Nov;261(11):2234–43.  
doi:10.1007/s00415-014-7520-7

45.

Belaya K, Rodríguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME, et al. Mutations in *CHST13* cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. *Brain*. 2015 Sep;138(9):2493–504.  
doi:10.1093/brain/awv185

46.

Rodríguez Cruz PM, Sewry C, Beeson D, Jayawant S, Squier W, McWilliam R, et al. Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature. *Neuromuscular Disorders*. 2014 Dec;24(12):1103–10.  
doi:10.1016/j.nmd.2014.07.005

47.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016 Feb;17(2):103–17. doi:10.1038/nrn.2015.27

48.

Gilhus NE. Myasthenia Gravis. *New England Journal of Medicine*. 2016 Dec 29;375(26):2570–81. doi:10.1056/NEJMra1602678

49.

Kusner LL, Kaminski HJ. Myasthenia Gravis. In: *Neurobiology of Brain Disorders* [Internet]. Elsevier; 2015. p. 135–50. Available from:  
<https://linkinghub.elsevier.com/retrieve/pii/B9780123982704000100>  
doi:10.1016/B978-0-12-398270-4.00010-0

50.

Leung DG. Other Proven and Putative Autoimmune Disorders of the Peripheral Nervous System [Internet]. Vol. 1. Oxford University Press; 2017. Available from:

<http://oxfordmedicine.com/view/10.1093/med/9780199937837.001.0001/med-9780199937837-chapter-98> doi:10.1093/med/9780199937837.003.0098

51.

Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010 Aug 1;81(8):850–7. doi:10.1136/jnnp.2008.169367

52.

Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *The Lancet Neurology*. 2009 May;8(5):475–90. doi:10.1016/S1474-4422(09)70063-8

53.

Spillane J, Ermolyuk Y, Cano-Jaimez M, Lang B, Vincent A, Volynski KE, et al. Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca<sup>2+</sup> channels. *Neurology*. 2015 Feb 10;84(6):575–9. doi:10.1212/WNL.0000000000001225

54.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *New England Journal of Medicine*. 2016 Aug 11;375(6):511–22. doi:10.1056/NEJMoa1602489

55.

Orrell, Richard WBarclay, Chris. Diagnosis and management of motor neurone disease. *Practitioner* [Internet]. 260:17–21. Available from: <https://search.proquest.com/docview/1844334383/64C39DCAF3D346C0PQ/1?accountid=14511>

56.

Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. *British Medical Bulletin*. 2016 Sep;119(1):87–98. doi:10.1093/bmb/ldw026

57.

Fuller G, Manford M. Neurology: an illustrated colour text [Electronic resource]. 3rd ed. Edinburgh: Churchill Livingstone Elsevier; 2010. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=3669595080004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3669595080004761&institutionId=4761&customerId=4760)

58.

Motor neurone disease: assessment and management | Guidance and guidelines | NICE [Internet]. Available from: <https://www.nice.org.uk/guidance/ng42>

59.

Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. *Revue Neurologique*. 2016 Jan;172(1):37–45. doi:10.1016/j.neurol.2015.11.002

60.

Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotrophic Lateral Sclerosis*. 2012 Jan;13(1):1–10. doi:10.3109/17482968.2011.627589

61.

Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology*. 2015 Jun 2;84(22):2247–57. doi:10.1212/WNL.0000000000001642

62.

Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: State of the field and future directions. *Muscle & Nerve*. 2016 Feb;53(2):169–82. doi:10.1002/mus.24979

63.

Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2016;3:98–102. doi:10.1016/j.dadm.2016.05.005

64.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for *tau*-associated amyotrophic lateral sclerosis. *Science Translational Medicine*. 2017 Mar 29;9(383). doi:10.1126/scitranslmed.aai7866

65.

Vincent A. Unravelling the pathogenesis of myasthenia gravis. *Nature Reviews Immunology*. 2002 Oct;2(10):797–804. doi:10.1038/nri916

66.

Jacobson L, Polizzi A, Morriss-Kay G, Vincent A. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. *Journal of Clinical Investigation*. 1999 Apr 1;103(7):1031–8. doi:10.1172/JCI5943

67.

Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. *Experimental Neurology*. 2012 Apr;234(2):506–12. doi:10.1016/j.expneurol.2012.01.025

68.

Konecny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. *Journal of Anatomy*. 2014 Jan;224(1):29–35. doi:10.1111/joa.12034

69.

Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. *PLoS ONE*. 2013 Nov 7;8(11). doi:10.1371/journal.pone.0080695

70.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016 Feb;17(2):103–17. doi:10.1038/nrn.2015.27

71.

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry*. 2016 Aug;138:6–31. doi:10.1111/jnc.13654

72.

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry*. 2016 Aug;138:193–210. doi:10.1111/jnc.13656

73.

Volume 58, Issue 3, March 2016. Volume 58, Issue 3, March 2016 [Internet]. Available from: <https://link.springer.com/journal/12031/58/3>

74.

Badders NM, Korff A, Miranda HC, Vuppala PK, Smith RB, Winborn BJ, et al. Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. *Nature Medicine*. 2018 Mar 5;24(4):427–37. doi:10.1038/nm.4500

75.

Beitel LK, Alvarado C, Mokhtar S, Paliouras M, Trifiro M. Mechanisms Mediating Spinal and Bulbar Muscular Atrophy: Investigations into Polyglutamine-Expanded Androgen Receptor Function and Dysfunction. *Frontiers in Neurology*. 2013;4. doi:10.3389/fneur.2013.00053

76.

Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, et al. Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy. *Neuron*. 2014 Apr;82(2):295–307. doi:10.1016/j.neuron.2014.03.001

77.

Fratta P, Nirmalananthan N, Masset L, Skorupinska I, Collins T, Cortese A, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. *Neurology*. 2014 Jun 10;82(23):2077–84. doi:10.1212/WNL.0000000000000507

78.

Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, et al. Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy. *Cell Reports*. 2014 May;7(3):774–84. doi:10.1016/j.celrep.2014.02.008

79.

Malik B, Nirmalananthan N, Bilisland LG, La Spada AR, Hanna MG, Schiavo G, et al. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. *Human Molecular Genetics*. 2011 May 1;20(9):1776–86. doi:10.1093/hmg/ddr061

80.

Malik B, Nirmalananthan N, Gray AL, La Spada AR, Hanna MG, Greensmith L. Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. *Brain*. 2013 Mar;136(3):926–43. doi:10.1093/brain/aws343

81.

Manzano R, Sorarú G, Grunseich C, Fratta P, Zuccaro E, Pennuto M, et al. Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2018 Aug;89(8):808–12. doi:10.1136/jnnp-2017-316961

82.

Milioto C, Malena A, Maino E, Polanco MJ, Marchioretti C, Borgia D, et al. Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. *Scientific Reports*. 2017 Dec;7(1). doi:10.1038/srep41046